您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Sonidegib diphosphate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sonidegib diphosphate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Sonidegib diphosphate图片
CAS NO:1218778-77-8
包装与价格:
包装价格(元)
2 mg电议
10 mg电议
50 mg电议
100 mg电议
1 mL*10 mM(in DMSO)电议

产品名称
Erismodegib diphosphate
NVP-LDE 225 diphosphate
LDE225 Diphosphate
产品介绍
EriSmodegib diphosphate 是 Smo 的选择性拮抗剂,能够抑制鼠 Smo (IC50:1.3 nM)和人 Smo (IC50:2.5 nM)。

产品描述

Erismodegib diphosphate is an effective and selective Smo antagonist (IC50: 1.3 nM and 2.5 nM for mouse and human Smo in a binding assay, respectively).

体外活性

Erismodegib diphosphate, a small molecule, clinically investigated SMO inhibitor. Erismodegib diphosphate is used alone and in combination with Nilotinib, inhibits the Hh pathway in CD34+ chronic phase (CP)-chronic myeloid leukaemia (CML) cells, reducing the number and self-renewal capacity of CML leukaemia stem cell (LSC). In a similar fashion to cyclopamine, Erismodegib interacts directly with SMO, to reduce the expression of downstream Hh signaling targets. The IC50 values for Erismodegib diphosphate for the major human CYP450 drug-metabolizing enzymes are greater than 10 μM. Primary CD34+ CP-CML cells are cultured in serum-free media (SFM)±Erismodegib for 6, 24, and 72 hours (h). At 72 h, while there is variability between the biological samples, GLI1 is obviously downregulated following exposure to Erismodegib (10 nM; 0.78-fold and 100 nM; 0.73-fold, respectively (p<0.01)[2].

体内活性

Erismodegib diphosphate is a weak base with a measured pKa of 4.2 and exhibits relatively poor aqueous solubility. Erismodegib diphosphate demonstrates dose-related antitumor activity after 10 days of oral administration of a suspension of the diphosphate salt, in the subcutaneous Ptch+/-p53-/- medulloblastoma allograft mouse model. Bone marrow cells and spleen cells from a subset of treated mice are transplanted into secondary recipient mice. Erismodegib diphosphate (5 mg/kg/day; once daily) obviously inhibits tumor growth, corresponding to a T/C value of 33% (p<0.05 as compared to vehicle controls). Erismodegib affords 51 and 83% regression respectively when dosed at 10 and 20 mg/kg/day qd [1]. Transplantation of either bone marrow (BM) or spleen cells from mice treated with Erismodegib diphosphate+ Nilotinib results in reduced white cell count (WCC) and reduces leukaemia development in secondary recipients compared to Erismodegib or Nilotinib alone[2].

Cas No.

1218778-77-8

分子式

C26H32F3N3O11P2

分子量

681.49

别名

Erismodegib diphosphate;NVP-LDE 225 diphosphate;LDE225 diphosphate

储存和溶解度

H2O:Insoluble,Need ultrasonic
DMSO:99 mg/mL(145.27 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years